Outcomes of Nonagenarians with Acute Myocardial Infarction with or without Coronary Intervention.
Seok OhMyung Ho JeongKyung Hoon ChoMin Chul KimDoo Sun SimYoung Joon HongJu Han KimYoungkeun AhnPublished in: Journal of clinical medicine (2022)
Percutaneous coronary intervention (PCI) is the mainstay treatment of acute myocardial infarction (AMI); however, many clinicians are reluctant to perform PCI in the elderly population. This study aimed to compare the clinical outcomes of PCI versus medical therapy in nonagenarian Korean patients with AMI. We compared the clinical outcomes of nonagenarian patients with AMI with or without PCI. From the pooled data, based on a series of Korean AMI registries during 2005-2020, 467 consecutive patients were selected and categorized into two groups: the PCI and no-PCI groups. The primary endpoint was 1-year major adverse cardiac event (MACE), a composite of all-cause death, non-fatal myocardial infarction, and any revascularization. Among the 467 participants, 68.5% received PCI. The PCI group had lower proportions of Killip classes III-IV, previous heart failure, and left ventricular ejection fraction <40%, but had higher proportions of all prescribed medications and STEMI diagnosis. The 1-year MACE and all-cause death were higher in the no-PCI group, although partially attenuated post-IPTW. Our study showed that nonagenarian patients with AMI undergoing PCI had better clinical outcomes than those without PCI. Nonetheless, further investigation is needed in the future to elucidate whether PCI is beneficial for this population.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- left ventricular
- st segment elevation myocardial infarction
- coronary artery disease
- st elevation myocardial infarction
- antiplatelet therapy
- acute coronary syndrome
- coronary artery bypass grafting
- ejection fraction
- heart failure
- atrial fibrillation
- coronary artery bypass
- aortic stenosis
- coronary artery
- clinical trial
- emergency department
- hypertrophic cardiomyopathy
- end stage renal disease
- type diabetes
- prognostic factors
- metabolic syndrome
- artificial intelligence
- bone marrow
- stem cells
- phase iii
- newly diagnosed
- mesenchymal stem cells
- skeletal muscle
- study protocol